SAN DIEGO, June 02, 2025 -- BioAtla, Inc. (Nasdaq: BCAB) (the “Company”), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the...
Cerexa to be acquired by Forest Laboratories for $480 million plus potential $100 million milestone payment
News | 12. 14. 2006
Cerexa
Cerexa Inc. today announced it has entered into a definitive agreement to be acquired by Forest Laboratories Inc. (NYSE: FRX) for $480 million plus a potential $100 million milestone payment.
